Over the past few years, Canadian biotech innovation has come out of its “quiet period” and is ripe for investment and return. In 2019, we saw Canada’s largest acquisition ($1 Billion acquisition of Clementia) and this year, we had a top NASDAQ IPO (Repare Therapeutics). As more venture capital and large companies look North for innovation, the reputation and valuation of Canadian biotech is on the rise.
Speakers:
Christopher Viehbacher, Managing Partner, Gurnet Point Capital, former CEO and Member of the Board of Directors of Sanofi

Lloyd Segal, President & Chief Executive Officer, Repare Therapeutics 
Moderator:
Cheryl Reicin,  Partner, Torys LLP | Chair of Life Sciences Practice